Anzeige
Mehr »
Login
Sonntag, 19.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
100-Milliarden-Dollar-Marke: Wie die strategische Vision eines Unternehmens historischem Meilenstein passt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2YN35 | ISIN: DE000A2YN355 | Ticker-Symbol: CA1
Xetra
17.01.25
17:36 Uhr
25,000 Euro
+1,200
+5,04 %
1-Jahres-Chart
CIRCUS SE Chart 1 Jahr
5-Tage-Chart
CIRCUS SE 5-Tage-Chart
RealtimeGeldBriefZeit
23,80024,60018.01.
23,80024,80017.01.
ACCESS Newswire
289 Leser
Artikel bewerten:
(1)

MWB Research Initiates Coverage on Circus SE with a "Buy" Recommendation and 75 Euro Price Target

Finanznachrichten News

MUNICH, DE / ACCESS Newswire / January 18, 2025 / MWB Research, one of Europe's largest independent research firms, has initiated coverage on Circus SE (XETRA:CA1.DE), issuing a "Buy" recommendation with a price target of 75 Euros. This valuation represents a 215% increase compared to the previous trading day's closing price on XETRA.

Circus SE specializes in Physical AI, a field that combines artificial intelligence with physical systems to enable autonomous operation in real-world settings. Its flagship product, the Circus Autonomy One (CA-1), has gained recognition for its ability to address challenges in the food service sector, particularly in areas such as labor shortages and operational efficiency. According to the company, the CA-1 robot integrates AI-driven software with advanced robotics, allowing it to perform tasks traditionally handled by human workers.

The recommendation from MWB Research comes shortly after Circus SE's announcement of its acquisition of FullyAI, a European company specializing in Agentic AI. This technology focuses on enhancing the decision-making capabilities of autonomous systems. Circus SE has stated that it plans to integrate FullyAI's technology into its Physical AI platforms, including the CA-1, with the aim of advancing human-robot interaction. The acquisition is seen as a strategic move to bolster the company's position in the automation and robotics sector.

Circus SE has reported that it has secured over 8,600 pre-orders for the CA-1 since the product's launch. These orders, which span multiple industries, represent a potential annual revenue of approximately 1.1 billion euros from recurring AI software fees and an additional 1.7 billion euros from robotic sales. The pre-orders reflect significant interest in the application of autonomous systems within industries that rely on labor-intensive processes.

MWB Research's analysis highlights the broader implications of Circus SE's technology for the automation sector. The firm emphasized the potential for substantial disruption in the food service industry, citing its size and reliance on manual labor. According to the report, the industry's scale exceeds that of the global automotive market, presenting opportunities for companies like Circus SE to introduce solutions that can address inefficiencies and reduce costs.

The analysts at MWB Research noted that Circus SE's approach to Physical AI positions it uniquely within the automation landscape. Unlike traditional robotics, which often require extensive human oversight, Physical AI systems are designed to operate autonomously, combining advanced sensing, reasoning, and decision-making capabilities. This distinction could make Circus SE a key player in shaping the adoption of AI-powered systems across various industries.

The report also discusses the competitive landscape, acknowledging other players in the robotics and AI sectors while highlighting Circus SE's focus on the practical application of autonomous systems. Analysts believe this focus could enable the company to establish a strong foothold in the market, particularly as industries increasingly adopt automation to address workforce challenges.

Circus SE's management has described the integration of FullyAI's technology as a step toward unlocking new possibilities for human-robot collaboration. The company has stated that its goal is to develop systems that can perform complex tasks efficiently and safely, reducing the reliance on human labor for repetitive or physically demanding work.

Investors and industry stakeholders can access the full report from MWB Research, which provides detailed insights into the company's technology, market potential, and growth prospects. The report is available at:https://research-hub.de/companies/circus-se.

About Circus SE

Circus SE is a Germany-based company specializing in Physical AI, a field that integrates artificial intelligence with robotics to create systems capable of autonomous operation in real-world environments. The company's flagship product, the Circus Autonomy One (CA-1), is designed to enhance efficiency in the food service industry and other labor-intensive sectors. Circus SE is focused on developing solutions that combine advanced technology with practical applications to address global challenges.

Media Contact

Organization: Circus SE
Contact Person Name: Maximilian Hartweg
Website: http://www.circus-group.com/
Email: ir@circus-group.com
Country: Germany

SOURCE: Circus SE



View the original press release on ACCESS Newswire

© 2025 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.